Loading clinical trials...

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes

NCT01107886•AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

Detailed Description

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with type 2 diabetes mellitus
•HbA1c ≥6.5%. (based on the last measured and documented laboratory measurement within 6 months)
•High risk for CV events -Established cardiovascular disease and/or multiple risk factors

Exclusion Criteria

•Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics
•Acute vascular event \<2months prior to randomisation

Locations (536)

Research Site

Birmingham, Alabama, United States

Research Site

Phoenix, Arizona, United States

Research Site

Tempe, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

Little Rock, Arkansas, United States

Research Site

Alhambra, California, United States

Research Site

Anaheim, California, United States

Research Site

Bakersfield, California, United States

Research Site

Burlingame, California, United States

Research Site

Duarte, California, United States

Key Dates

Start Date

May 1, 2010

Primary Completion Date

May 1, 2013

Completion Date

May 1, 2013

Last Updated

July 17, 2014

Enrollment

18,206

ACTUAL participants

Conditions

Type 2 Diabetes Mellitus

Interventions

Saxagliptin

DRUG

Placebo

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 17, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Human Immunodeficiency Virus (HIV) Food Insecurities

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease